Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bruker Cellular Analysis, Inc.CELL · Entity 109250 | Director · Chief Executive Officer | October 02, 2023 | October 03, 2023 |
| IsoPlexis CorpISO · Entity 115290 | Director | June 16, 2022 | June 21, 2022 |
| MESA LABORATORIES INC /CO/MLAB · Entity 5221 | President and CEO | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bruker Cellular Analysis, Inc.
Report date October 02, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-02 transaction · row 1
1 source rowRow 1 · 2023-10-02 · Disposition to issuer · Disposed 595,395 · Balance 0 F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-10-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-02 · Disposition to issuer · Disposed 645,294 · Balance 0 F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. F3: Reflects shares directly held by Anjou Perekh, TTEE The Anjou Parekh Spousal Lifetime Access Trust DTD 08/10/2023, of which the Reporting Person's spouse is the sole trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration").
F2: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration.
F3: Reflects shares directly held by Anjou Perekh, TTEE The Anjou Parekh Spousal Lifetime Access Trust DTD 08/10/2023, of which the Reporting Person's spouse is the sole trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
IsoPlexis Corp
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2032-06-16 | Direct | 89,047 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 89,047 · Balance 89,047 F1: Option vests in full on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the next annual shareholders meeting |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in full on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the next annual shareholders meeting
MESA LABORATORIES INC /CO/
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 7,093 |
Reported balance
After 2026-08-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-13 · Purchase · Acquired 7,093 · Balance 7,093 F1: Represents shares purchased directly in a private transaction from John Sullivan, Mesa Board Chair by the Anjou Parekh Lifetime Access Trust for which the reporting person's spouse serves as trustee. F2: Represents shares held by the Anjou Parekh Lifetime Access Trust for which the reporting person's spouse serves as trustee. The reporting person disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares purchased directly in a private transaction from John Sullivan, Mesa Board Chair by the Anjou Parekh Lifetime Access Trust for which the reporting person's spouse serves as trustee.
F2: Represents shares held by the Anjou Parekh Lifetime Access Trust for which the reporting person's spouse serves as trustee. The reporting person disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 3,739 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 17, 2026 15:49 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | PurchaseCommon Stock | 7,093 | $112.80 | $800,090.40 |
DisclosureSEC source: 0000724004-26-000084 · primary_doc.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,093 F1 · kind: Represents shares purchased directly in a private transaction from John Sullivan, Mesa Board Chair by the Anjou Parekh Lifetime Access Trust for which the reporting person's spouse serves as trustee. F2 · ownership.nature: Represents shares held by the Anjou Parekh Lifetime Access Trust for which the reporting person's spouse serves as trustee. The reporting person disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein. Read SEC document |
| April 14, 2026 Filed Apr 24, 2026 14:49 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | GrantRestricted Stock Units - 1 · Derivative | 34,807 | $0.00 | $0.00 |
DisclosureSEC source: 0000724004-26-000033 · primary_doc.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,807 Underlying: Common Stock · 34,807 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vest 1/3 on each anniversary date F3 · derivative.expiration_date: Not Applicable Read SEC document |
| April 14, 2026 Filed May 19, 2026 13:04 UTC Amendment | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | GrantRestricted Stock Units - 1 · Derivative | 35,236 | $0.00 | $0.00 |
DisclosureSEC source: 0000724004-26-000034 · primary_doc.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,236 Underlying: Common Stock · 35,236 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vest 1/3 on each anniversary date F3 · derivative.expiration_date: Not Applicable Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:42 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Disposition to issuerCommon Stock | 645,294 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019745 · doc4.xml · nonDerivative · entry 2 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F1 · price: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2 · price: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. F3 · ownership.nature: Reflects shares directly held by Anjou Perekh, TTEE The Anjou Parekh Spousal Lifetime Access Trust DTD 08/10/2023, of which the Reporting Person's spouse is the sole trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:42 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Disposition to issuerCommon Stock | 595,395 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019745 · doc4.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F1 · price: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker, and each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2 · price: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 4,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048185 · doc4.xml · derivative · entry 3 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,816 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 3,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048185 · doc4.xml · derivative · entry 2 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,788 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerCommon Stock, par value $0.001 per share | 3,739 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048185 · doc4.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 16:10 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | GiftCommon Stock | 645,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-095987 · tm2324970-1_4seq1.xml · nonDerivative · entry 2 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 645,294 F1 · kind: Represents a bona fide gift of 645,294 shares by the Reporting Person to Anjou Perekh, TTEE The Anjou Parekh Spousal Lifetime Access Trust DTD 08/10/2023, of which the Reporting Person's spouse is the sole trustee, in connection with estate planning purposes. F2 · ownership.nature: Reflects shares directly held by Anjou Perekh, TTEE The Anjou Parekh Spousal Lifetime Access Trust DTD 08/10/2023, of which the Reporting Person's spouse is the sole trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 16:10 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | GiftCommon Stock | 645,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-095987 · tm2324970-1_4seq1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,395 F1 · kind: Represents a bona fide gift of 645,294 shares by the Reporting Person to Anjou Perekh, TTEE The Anjou Parekh Spousal Lifetime Access Trust DTD 08/10/2023, of which the Reporting Person's spouse is the sole trustee, in connection with estate planning purposes. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 17:53 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 4,816 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036454 · doc4.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,816 Underlying: Common Stock · 4,816 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.exercise_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.expiration_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:34 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 317,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-029760 · tm237589-5_4seq1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240,689 F1 · shares: Represents an award of restricted stock units which vested in full on March 3, 2023. The restricted stock units were granted pursuant to the Issuer's 2020 Incentive Award Plan in lieu of a cash bonus earned for 2022. Restricted stock units were settled in shares of the Issuer's common stock upon vesting. F2 · balance_after: Includes 765,741 restricted stock units. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 16:46 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | Tax withholdingCommon Stock | 36,975 | $2.64 | $97,614.00 |
DisclosureSEC source: 0001104659-22-126646 · tm2232538-1_4.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,660 F1 · shares: Reflects shares sold by the Reporting Person pursuant to a pre-determined election in order to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · balance_after: Includes 765,741 restricted stock units. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 16:10 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | Tax withholdingCommon Stock | 150 | $2.53 | $379.50 |
DisclosureSEC source: 0001104659-22-125847 · tm2232312-1_4.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,635 F1 · shares: Reflects shares sold by the Reporting Person pursuant to a pre-determined election in order to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · balance_after: Includes 850,505 restricted stock units. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 19:19 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | Tax withholdingCommon Stock | 29,200 | $3.96 | $115,632.00 |
DisclosureSEC source: 0001567619-22-017383 · doc1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,785 F1 · shares: Reflects shares sold by the Reporting Person pursuant to a pre-determined election in order to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · balance_after: Includes 850,914 restricted stock units. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 17:23 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | Tax withholdingCommon Stock | 561 | $3.68 | $2,064.48 |
DisclosureSEC source: 0001567619-22-017239 · doc1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 989,985 F1 · shares: Reflects shares sold by the Reporting Person pursuant to a pre-determined election in order to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · balance_after: Includes 935,679 restricted stock units. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 13:45 UTC | IsoPlexis Corp ISO · Entity 115290 | GrantStock Option · Derivative | 89,047 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001062993-22-015244 · form4.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,047 Underlying: Common Stock · 89,047 shares Expires 2032-06-16 F1 · derivative.exercise_date: Option vests in full on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the next annual shareholders meeting Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 18:20 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | Tax withholdingCommon Stock | 31,531 | $5.22 | $164,591.82 |
DisclosureSEC source: 0001567619-22-012800 · doc1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 990,546 F1 · balance_after: Includes 937,312 restricted stock units. Read SEC document |
| May 28, 2022 Filed Jun 1, 2022 16:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,702 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033194 · doc4.xml · derivative · entry 3 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,702 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 18, 2021. In accordance with the terms of the RSU award, the award vested as to 2,702 shares on May 11, 2022. Pursuant to a deferral election made by the Reporting Person, all of the shares underlying the RSUs were delivered on May 28, 2022. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 18, 2021. In accordance with the terms of the RSU award, the award vested as to 2,702 shares on May 11, 2022. Pursuant to a deferral election made by the Reporting Person, all of the shares underlying the RSUs were delivered on May 28, 2022. Read SEC document |
| May 28, 2022 Filed Jun 1, 2022 16:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 1,037 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033194 · doc4.xml · derivative · entry 2 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on February 1, 2021. In accordance with the terms of the RSU award, the award vested as to 1,037 shares on May 18, 2021. Pursuant to a deferral election made by the Reporting Person, all of the shares underlying the RSUs were delivered on May 28, 2022. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on February 1, 2021. In accordance with the terms of the RSU award, the award vested as to 1,037 shares on May 18, 2021. Pursuant to a deferral election made by the Reporting Person, all of the shares underlying the RSUs were delivered on May 28, 2022. Read SEC document |
| May 28, 2022 Filed Jun 1, 2022 16:53 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 3,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033194 · doc4.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| May 11, 2022 Filed May 13, 2022 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 3,788 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028939 · doc4.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788 Underlying: Common Stock · 3,788 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until May 28, 2022. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until May 28, 2022. Read SEC document |
| March 10, 2022 Filed Mar 22, 2022 21:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 678,118 | $0.00 Strike: $5.69 | $0.00 |
DisclosureSEC source: 0001567619-22-007363 · doc1.xml · derivative · entry 3 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,118 Underlying: Common Stock · 678,118 shares Expires 2032-03-09 F3 · derivative.exercise_date: The stock option will vest subject to both a service-based requirement and a performance-based requirement, where (i) the service-based requirement shall be satisfied with respect to 20% of the stock option shares on each anniversary of the Appointment Date, and (ii) the performance-based requirement will be satisfied with respect to 20% of the stock options shares based on achieving each of the stock option price goals of 200%, 400%, 800%, 1500% and 2000% of $5.93, which such stock price goals must be achieved by the seventh anniversary of the Appointment Date. Read SEC document |
| March 10, 2022 Filed Mar 22, 2022 21:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 339,059 | $0.00 Strike: $5.69 | $0.00 |
DisclosureSEC source: 0001567619-22-007363 · doc1.xml · derivative · entry 2 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,059 Underlying: Common Stock · 339,059 shares Expires 2032-03-09 F2 · derivative.exercise_date: The stock option will vest in twelve (12) equal quarterly installments on each quarterly anniversary from the Appointment Date. Read SEC document |
| March 10, 2022 Filed Mar 22, 2022 21:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 1,017,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007363 · doc1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022,077 F1 · shares: Represents an award of restricted stock units which will vest in twelve (12) equal quarterly installments beginning from the date that is one quarterly anniversary after March 9, 2022 (the "Appointment Date"). Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:17 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001567619-21-016931 · doc1.xml · derivative · entry 2 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4,900 shares Expires 2031-09-06 F2 · derivative.exercise_date: The stock option will vest in 36 equal monthly installments until fully vested on September 7, 2024. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:17 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 4,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-016931 · doc1.xml · nonDerivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 F1 · shares: Represents an award of restricted stock units which will vest with respect to one-third of the shares on September 7, 2022, and will vest with respect to the remainder of the shares in equal quarterly installments thereafter until fully vested on September 7, 2024. The restricted stock units will be settled in shares of the Issuer's common stock upon vesting. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 2,702 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034549 · doc4.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702 Underlying: Common Stock · 2,702 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until May 28, 2022. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until May 28, 2022. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 1,037 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007396 · doc4.xml · derivative · entry 1 Kadia Siddhartha · CIK 0001573666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037 Underlying: Common Stock · 1,037 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on May 18, 2021. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on May 18, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.